Page last updated: 2024-08-24

lamivudine and delavirdine mesylate

lamivudine has been researched along with delavirdine mesylate in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fong, HH; Mesecar, AD; Nguyen, MC; Nguyen, QC; Nguyen, VH; Pezzuto, JM; Santarsiero, BD; Soejarto, DD; Tan, GT1
Chen, W; De Clercq, E; Liu, X; Liu, Z; Pannecouque, C; Zhan, P1
Balzarini, J; Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Yu, M; Zhan, P1
Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Li, X; Liang, X; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Zhan, P1
Chen, X; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, W; Liu, X; Meng, Q; Pannecouque, C; Zhan, P1

Other Studies

5 other study(ies) available for lamivudine and delavirdine mesylate

ArticleYear
New 3-O-acyl betulinic acids from Strychnos vanprukii Craib.
    Journal of natural products, 2004, Volume: 67, Issue:6

    Topics: Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Betulinic Acid; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Molecular Structure; Pentacyclic Triterpenes; Plant Leaves; Plants, Medicinal; Stereoisomerism; Strychnos; Triterpenes; Tumor Cells, Cultured

2004
Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
    European journal of medicinal chemistry, 2014, Nov-24, Volume: 87

    Topics: Anti-HIV Agents; Catalytic Domain; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Niacinamide; Protein Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured

2014
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
    European journal of medicinal chemistry, 2015, Mar-06, Volume: 92

    Topics: Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Nitrogen; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Sulfones

2015
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
    European journal of medicinal chemistry, 2015, Mar-26, Volume: 93

    Topics: Anti-HIV Agents; Chemistry Techniques, Synthetic; Computational Biology; Drug Design; HIV Reverse Transcriptase; HIV-1; Imidazoles; Molecular Docking Simulation; Protein Conformation; Pyrazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2015
Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
    European journal of medicinal chemistry, 2016, Jun-10, Volume: 115

    Topics: Anti-HIV Agents; Binding Sites; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication

2016